Beta-Blocker Use and Mortality Among Patients with Systolic Heart Failure and Pacemaker Rhythm

Andrew Perry; Aldo Maggioni; Luigi Tavazzi; Wayne C. Levy

doi:10.1002/ehf2.14353

Abstract

1 min read

Beta-blocker therapy is associated with improved survival among patients with heart failure and a pacemaker rhythm on ECG. Further studies are necessary to analyse differences between atrial and ventricular pacemakers.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Letter2021

Clinical outcomes with digoxin vs. beta‐blocker for heart rate control in permanent atrial fibrillation with heart failure

Arnaud Bisson, Wern Yew Ding, Alexandre Bodin, Professor Gregory Lip, Laurent Fauchier

Letter2022

Stroke risk stratification in patients with heart failure and sinus rhythm

Dimitrios Sagris, Eduard Shantsila, Professor Gregory Lip

Article2025

Impact of digoxin versus beta-blocker in patients with coexistent atrial fibrillation and heart failure: a target trial emulation

Lin Liu, Anping Cai, Jiayi Huang, Wenli Gu, Ran Guo, Jingnan Zhang, Haochen Xuan, Yap‐Hang Chan, Aimin Xu, Bernard M. Y. Cheung, Professor Gregory Lip, Kai-Hang Yiu

Article2021

Are the results of the RATE-AF trial reproducible in daily practice? Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation

Laurent Fauchier, Arnaud Bisson, Alexandre Bodin, P Spiesser, Nicolas Clémenty, Bernard Pierre, D Babuty, Professor Gregory Lip

Article2001

Practical Recommendations for the Use of ACE Inhibitors, Beta-Blockers and Spironolactone in Heart Failure: Putting Guidelines Into Practice

John J.V. McMurray, Cohen‐Solal Alain, Rainer Dietz, Eichhorn Eric, Erhardt Leif, Richard Hobbs, Aldo Maggioni, Pina Ileana, Soler‐Soler Jordi, Karl Swedberg